Healthcare Finance News November 24, 2025
The new direct-to-employer model supports rising demand for FDA-approved obesity medications.
Eli Lilly and Novo Nordisk are collaborating with Waltz Health to launch direct-to-employer access for obesity management medications.
Waltz Health gave no information on the prices of GLP-1 drugs available to employees in the plan.
It said the plan offers employers transparent pricing and a new pathway to offer obesity meds as a part of benefits.
An estimated half of corporate health plans cover these medicines for employees with diabetes, but only one in five provide coverage for the drugs for weight management, according to Waltz Health.
“Employers continue to tell us they want to better support their employees’ health but face real challenges in providing coverage...
Today's Sponsors
Today's Sponsor